Alzheimer’s Drug Results Send Stocks Soaring, But Experts Temper Expectations After String Of Failures Against Disease

Biogen and Eisai announced that the drug slowed the progression of Alzheimer’s disease and reduced the amount of clumps of a protein called beta amyloid that build up in the brains of patients. The data cheered even skeptics that have been burned by decades of failed Alzheimer's drugs. But they did warn about getting too excited, as the study is preliminary.

from Kaiser Health News https://ift.tt/2m1DRTr